Amidst continued activity in the Hong Kong IPO market, Good Doctor Cloud Healthcare has chosen to make a second attempt at listing.

Compared to its first application, this submission features more complete documentation and a tighter schedule.

However, changes in the underwriting lineup, coupled with its financial structure and pressure from a valuation adjustment mechanism, make this listing sprint appear challenging.

A "Pinduoduo" for Healthcare

On April 10, Sichuan Good Doctor Cloud Healthcare Technology Group Co., Ltd. (hereinafter referred to as "Good Doctor Cloud Healthcare") once again submitted a listing application to the Hong Kong Stock Exchange.

This follows the lapse of its previous application by just over ten days, clearly indicating time pressures driving the move.

The most immediate change for this second application is the intermediary team. During its first application in September 2025, the company appointed Haitong International and CLSA as joint sponsors, with CICC Hong Kong as financial advisor. However, for this current listing effort, CLSA withdrew on April 8, 2026, leaving Haitong International as the sole sponsor.

In contrast, the previous prospectus drew attention for a different reason. It was noted that the name of the company's founder, Geng Funeng, was mistakenly written as "Geng Funeng" three times.

Such a basic error is uncommon in serious IPO documents and suggests the company's initial preparation for the capital markets was somewhat crude.

But looking at the broader timeline, the story of Good Doctor Cloud Healthcare has far more substance than this erroneous prospectus might imply.

Geng Funeng was born in June 1956 in a rural village in Yuexi County, Liangshan Prefecture, Sichuan. His childhood experiences gathering herbs in the mountains with his father and brother forged a deep connection with traditional Chinese medicine.

In 1986, he opened a Chinese medicinal materials purchasing office in Dechang County, Liangshan, starting a trade business in medicinal materials and establishing the "Jianengda" brand.

As the business grew, he expanded into prepared medicines and identified a core industry issue: inconsistent drug quality. It was from this point that he decided to extend upstream in the supply chain, engaging in his own herb cultivation and drug production.

In 1995, Jianengda entered the pharmaceutical manufacturing sector by investing in Panxi Pharmaceutical Factory. The following year, Geng Funeng established an aconite planting base in Butuo County, Liangshan, promoting cultivation and unified repurchasing to control drug quality at the source.

In 1997, the "Jianengda" brand was renamed "Good Doctor," and the trademark was registered in 2000.

Today, the Good Doctor Pharmaceutical Group, led by Geng Funeng, has developed into a large enterprise group focused on biomedicine within the broader "Great Health" industry. It oversees 37 wholly-owned subsidiaries, 14 GMP-certified production plants, 2 GAP-certified herb bases, has over 400 registered drugs, and employs more than 20,000 staff.

Good Doctor Cloud Healthcare, which is now seeking a Hong Kong IPO, was established by the Good Doctor Pharmaceutical Group in Chengdu in January 2016.

After several years of development, Good Doctor Cloud Healthcare has grown into a leading provider of services to primary healthcare terminals in China.

According to the prospectus, as of the end of 2025, the company had served over 670,500 primary healthcare terminal customers, including 390,100 primary medical institutions and 280,400 retail pharmacies, covering over 99% of China's counties.

The core of its business is direct drug supply and bundled services. It penetrates the primary market with low-priced medicines while also layering on specialized disease diagnosis and treatment solutions, along with diagnostic testing solutions, to increase user stickiness and average customer spending.

In terms of scale, the company has indeed achieved a significant position. From 2023 to 2025, its revenues were approximately RMB 3.065 billion, RMB 3.264 billion, and RMB 3.823 billion, respectively, representing a compound annual growth rate of about 11.7% over the three years.

Based on 2024 revenue, it ranked second in China's primary healthcare direct drug supply market, with an 11.3% market share. In the segment for primary healthcare diagnostic testing solutions, it held a 12.8% market share, ranking first.

It is worth noting that Good Doctor Cloud Healthcare's proprietary brand (OEM) drug business is key to its revenue.

From 2023 to 2025, revenue from this business was approximately RMB 1.795 billion, RMB 1.841 billion, and RMB 2.027 billion, respectively, accounting for more than half of total revenue.

The company states in its prospectus that its proprietary brand drug business "helps clients reduce their unit procurement cost by up to 50% under optimal conditions."

It is precisely this strategy of direct supply at low prices that has earned Good Doctor Cloud Healthcare the nickname "the Pinduoduo of healthcare."

Pressure from a RMB 600 Million Repurchase Obligation

Despite逐年增长的收入, Good Doctor Cloud Healthcare's profit performance has been unstable.

From 2023 to 2025, the company's net profit was approximately RMB 62.479 million, RMB 37.806 million, and RMB 54.052 million, respectively, corresponding to net profit margins of just 2.0%, 1.2%, and 1.4%.

In other words, for every RMB 100 of medicine sold, the profit retained was at most RMB 2.

More notably, the gross profit margin has been declining, dropping from 29.9% in 2023 to 22.9% in 2025, showing a持续走低 trend.

The reason is not complicated. In a model that trades price advantage for market share, offering lower margins is almost an inevitable choice. Furthermore, as sales scale increases, sales costs also rise.

This means that while the company is profitable at scale, there is room for improvement in the quality of its profits. If price competition intensifies or the policy environment changes, profits could easily be eroded.

Simultaneously, Good Doctor Cloud Healthcare's ownership structure and family-centric nature add another layer for observation.

Currently, the company remains firmly controlled by the Geng family. Prior to the IPO, Geng Funeng and his family members collectively control approximately 65.99% of the equity and voting rights through several entities.

Among them, Geng Funeng's daughter, Geng Jie, holds a 21.21% stake through Cloud Healthcare Technology (Hong Kong) Limited. Geng Jie's brother, Geng Yuefei, currently the General Manager of Good Doctor Pharmaceutical Group, also holds significant interests in Good Doctor Cloud Healthcare and serves as a non-executive director.

Geng Jie is 39 years old, a Canadian citizen, and currently serves as the Board Chairwoman and Executive Director of Good Doctor Cloud Healthcare.

After obtaining a Bachelor's degree in Mathematics from the University of Waterloo, Canada, in June 2009, she returned to China to gain experience in the family business, starting as a Product Procurement Manager.

In July 2012, she joined the Good Doctor Pharmaceutical Group, assisting her father Geng Funeng, and successively held the positions of Assistant to the Chairman of the Board and Executive Vice General Manager.

In 2019, Geng Funeng formally handed over the management of Good Doctor Cloud Healthcare to Geng Jie. When she joined the company in July of that year, she was still the Assistant to the Chairman of the Board and Group Finance Vice President of Good Doctor Pharmaceutical Group.

Besides Geng Jie, the company's other two Executive Directors are CEO Su Yazhou, aged 40, and CTO Xue Yuan (Geng Jie's spouse), aged 43.

Currently, the company faces more immediate pressure related to clauses in its pre-IPO investment agreements.

The prospectus discloses that if the company fails to complete a qualified listing or merger and acquisition by December 31, 2026, it is obligated to repurchase shares from its Series A, Series B, and pre-IPO investors. The repurchase price would be 1 times or 1.2 times the principal investment amount, plus annualized interest of 6% or 8%.

Based on available information, the amounts involved in these clauses are substantial: Series A investment of RMB 143 million, Series B investment of RMB 20 million, and an additional approximately RMB 353 million in financing raised in 2025 (including share issuance and transfers). If triggered, the redemption would significantly increase cash flow pressure.

As of February 28, 2026, Good Doctor Cloud Healthcare's total debt stood at RMB 679 million, of which the liability for redeemable equity shares amounted to a high RMB 633 million.

This seems to explain why the company swiftly refiled its application after the first prospectus lapsed. For Good Doctor Cloud Healthcare, this is not just a fundraising exercise; it resembles a timed mission.

If the company successfully lists, its debt structure will be optimized, and its brand and financing capabilities will be enhanced. However, if the listing process encounters obstacles, the clauses in the investment agreements could quickly translate into real financial pressure.

With just over eight months remaining until the deadline, the most urgent task for Good Doctor Cloud Healthcare is to successfully complete its listing before the repurchase obligation is triggered.